Blog

In recent years, the adolescent and young adult (AYA) cancer survivor population has gained increasing attention within oncological research, particularly due to their unique psychosocial needs that differ markedly from both pediatric and older adult populations. However, much of the foundational research into these challenges

Artificial intelligence is rapidly redefining the landscape of medical diagnostics, promising unprecedented capabilities in interpreting complex imaging data. A groundbreaking study spearheaded by researchers at Mass General Brigham, alongside collaborators from Boston Children’s Hospital and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, has unveiled a

In a groundbreaking advancement for prostate cancer diagnosis, researchers have developed an innovative ultrasound molecular imaging technique aimed explicitly at the early detection of castration-resistant prostate cancer (CRPC). This new approach leverages the unique properties of microbubbles modified with Neuropilin-2 (NRP2), a protein increasingly expressed

Long non-coding RNAs (lncRNAs) are emerging as pivotal regulators within the tumor microenvironment (TME), reshaping our understanding of cancer biology and opening new avenues for therapeutic intervention. Defined as RNA molecules longer than 200 nucleotides that do not encode proteins, lncRNAs were once deemed transcriptional

In a groundbreaking effort to redefine treatment paradigms for oligometastatic prostate cancer (OMPC), researchers have launched a multicenter, randomized controlled trial investigating the potential advantages of neoadjuvant radiohormonal therapy in combination with robotic-assisted radical prostatectomy (RARP). This novel approach aims to challenge the current standard

In the evolving landscape of lung cancer treatment, the integration of immune checkpoint inhibitors (ICIs) with conventional chemotherapy regimens has marked a significant milestone, offering renewed hope for improved survival outcomes. Yet, as these combination therapies gain prominence, the complexity of their safety profiles warrants

In a significant advancement for the field of cancer immunology, Moffitt Cancer Center has unveiled a groundbreaking podcast titled The ImmunoVerse. Spearheaded by the institution’s President and CEO, Dr. Patrick Hwu, a distinguished tumor immunologist, this innovative series promises to illuminate the rapidly evolving landscape

In the ever-evolving landscape of oncology, small cell carcinoma (SmCC) of the bladder remains one of the most enigmatic and aggressive forms of malignancy. Its rarity poses significant challenges to both diagnosis and treatment, often leaving clinicians grappling with limited understanding and therapeutic options. However,

In the evolving landscape of cancer treatment, immunotherapy has emerged as a revolutionary approach, particularly for patients with advanced non-small cell lung cancer (aNSCLC). Despite significant progress, predicting which patients will benefit adequately from immune checkpoint inhibitors (ICIs) remains a critical challenge for oncologists worldwide.

In a groundbreaking development that could reshape our understanding of cancer progression and treatment, researchers from leading institutions including the Francis Crick Institute, University College London (UCL), Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have unveiled pivotal findings linking age-associated blood cell mutations